141 related articles for article (PubMed ID: 7530135)
1. Idarubicin, intermediate-dose cytarabine, etoposide, and granulocyte-colony-stimulating factor are able to recruit CD34+/HLA-DR- cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia.
Carella AM; Frassoni F; Podestá M; Pungolino E; Pollicardo N; Ferrero R; Soracco M
J Hematother; 1994; 3(3):199-202. PubMed ID: 7530135
[TBL] [Abstract][Full Text] [Related]
2. Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia.
Carella AM; Podesta M; Frassoni F; Raffo MR; Pollicardo N; Pungolino E; Vimercati R; Sessarego M; Parodi C; Rabitti C
Bone Marrow Transplant; 1993 Sep; 12(3):267-71. PubMed ID: 7694724
[TBL] [Abstract][Full Text] [Related]
3. Quality of IL-3 and G-CSF-mobilized peripheral blood stem cells in patients with early chronic phase CML.
Heinzinger M; Waller CF; Rosenstiel A; Scheid S; Burger KJ; Lange W
Leukemia; 1998 Mar; 12(3):333-9. PubMed ID: 9529127
[TBL] [Abstract][Full Text] [Related]
4. Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha.
Carella AM; Simonsson B; Link H; Lennard A; Boogaerts M; Gorin NC; Tomas-Martinez JF; Dabouz-Harrouche F; Gautier L; Badri N
Br J Haematol; 1998 Apr; 101(1):111-8. PubMed ID: 9576191
[TBL] [Abstract][Full Text] [Related]
5. Idarubicin-containing regimen and G-CSF are capable of recruiting CD34+/DR- cells with high proliferative potential which sustain Ph-negative polyclonal hematopoiesis.
Carella AM; Podestá M; Pollicardo N; Pungolino E; Raffo MR; Ferrero R; Bergamaschi G; Rosti V; Cazzola M; Saglio G
Leukemia; 1994 Jan; 8(1):212-3. PubMed ID: 7507192
[No Abstract] [Full Text] [Related]
6. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F
Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
[TBL] [Abstract][Full Text] [Related]
7. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
8. Preliminary results of stem cell mobilization in chronic myeloid leukemia with a moderate intensity chemotherapy regimen and G-CSF or G-CSF plus IL-3.
Aulitzky WE; Neubauer A; Kolbe K; Schneller F; Busemann C; Schleiermacher E; Peschel C; Siegert W; Huber C; Huhn D
Bone Marrow Transplant; 1996 May; 17 Suppl 3():S67-9. PubMed ID: 8769707
[TBL] [Abstract][Full Text] [Related]
9. Therapy of acute phase chronic myelogenous leukemia with intensive chemotherapy, blood cell autotransplant and cyclosporine A.
Carella AM; Gaozza E; Raffo MR; Carlier P; Frassoni F; Valbonesi M; Lercari G; Sessarego M; Defferrari R; Guerrasio A
Leukemia; 1991 Jun; 5(6):517-21. PubMed ID: 1676080
[TBL] [Abstract][Full Text] [Related]
10. Collection, analysis and transplantation of Ph-negative blood precursor cells in chronic myeloid leukemia.
Frassoni F; Carella AM
Leukemia; 1996 Jun; 10 Suppl 2():s30-2. PubMed ID: 8649050
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens.
Deininger M; Pönisch W; Krahl R; Leiblein S; Edel E; Lange T; Fiedler F; Freund M; Franke A; Pasold R; von Grünhagen U; Herold M; Dölken G; Hoffmann FA; Uhle R; Schultze W; Steglich J; Schwarzer A; Richter P; Winkelmann C; Kettner E; Dachselt K; Subert R; Schwalbe E; Doepper J; Helbig W; Niederwieser D;
Bone Marrow Transplant; 2001 Jun; 27(11):1125-32. PubMed ID: 11551022
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells.
Verfaillie CM; Bhatia R; Steinbuch M; DeFor T; Hirsch B; Miller JS; Weisdorf D; McGlave PB
Blood; 1998 Sep; 92(5):1820-31. PubMed ID: 9716614
[TBL] [Abstract][Full Text] [Related]
13. Leukemic burden in subpopulations of CD34+ cells isolated from the mobilized peripheral blood of alpha-interferon-resistant or -intolerant patients with chronic myeloid leukemia.
Van den Berg D; Wessman M; Murray L; Tong J; Chen B; Chen S; Simonetti D; King J; Yamasaki G; DiGiusto R; Gearing D; Reading C
Blood; 1996 May; 87(10):4348-57. PubMed ID: 8639795
[TBL] [Abstract][Full Text] [Related]
14. Collection of Ph-negative progenitor cells from interferon responsive patients with chronic myeloid leukemia: effect of granulocyte-colony-stimulating factor mobilization.
Olavarria E; Parker S; Craddock C; Philpott N; Tiniakou M; Chase A; Kanfer E; Apperley JF; Goldman JM
Haematologica; 2000 Jun; 85(6):647-52. PubMed ID: 10870123
[TBL] [Abstract][Full Text] [Related]
15. Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia with different clinical stages.
Gopcsa L; Barta A; Banyai A; Foldi J; Kalasz L; Pajor L; Gidali J; Regeczy N; Paloczi K
Acta Haematol; 2001; 106(3):100-5. PubMed ID: 11713374
[TBL] [Abstract][Full Text] [Related]
16. Selective overshoot of Ph-negative blood hemopoietic cells after intensive idarubicin-containing regimen and their repopulating capacity after reinfusion.
Carella AM; Podestà M; Frassoni F; Pungolino E; Pollicardo N; Raffo MR; Ferrero R; Benvenuto F; Figari O; Giordano D
Stem Cells; 1993 Oct; 11 Suppl 3():67-72. PubMed ID: 7905325
[TBL] [Abstract][Full Text] [Related]
17. Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon.
Hernández-Boluda JC; Carreras E; Cervantes F; Marín P; Arellano-Rodrigo E; Rovira M; Solé F; Lloveras E; Espinet B; Ocejo A; Montserrat E
Haematologica; 2002 Jan; 87(1):17-22. PubMed ID: 11801461
[TBL] [Abstract][Full Text] [Related]
18. Autologous transplantation with Philadelphia-negative progenitor cells for patients with chronic myeloid leukaemia (CML) failing to attain a cytogenetic response to alpha interferon.
McBride NC; Cavenagh JD; Newland AC; Lillington DM; Murrell C; Kelsey SM
Bone Marrow Transplant; 2000 Dec; 26(11):1165-72. PubMed ID: 11149726
[TBL] [Abstract][Full Text] [Related]
19. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells.
Talpaz M; Kantarjian H; Liang J; Calvert L; Hamer J; Tibbits P; Durett A; Claxton D; Giralt S; Khouri I
Blood; 1995 Jun; 85(11):3257-63. PubMed ID: 7756658
[TBL] [Abstract][Full Text] [Related]
20. Myelosuppressive chemotherapy to mobilize normal stem cells in chronic myeloid leukemia.
Mehta J; Mijović A; Powles R; Pagliuca A; Singhal S; Czepulkowski B; Swansbury GJ; Treleaven J; Mufti GJ
Bone Marrow Transplant; 1996 Jan; 17(1):25-9. PubMed ID: 8673050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
